Clinical trial
Study of Heart and Renal Protection
NCT00125593 · University of Oxford, Other · Completed
Key facts
| NCT number | NCT00125593 |
|---|---|
| Title | Study of Heart and Renal Protection |
| Official title | Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial |
| Acronym | SHARP |
| Lead sponsor | University of Oxford, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry Schering-Plough National Health and Medical Research Council, Australia British Heart Foundation Medical Research Council |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Disease, Chronic |
| Intervention type | Drug |
| Interventions | Simvastatin 20 mg, Ezetimibe 10mg, Placebo |
| Enrollment | 9,438 |
| Start date | Jun 1, 2003 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Aug 1, 2005 |
| Last update posted | Feb 1, 2012 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: